SCHEMBL30765833

SCHEMBL30765833

CSc1ncc(NCc2ccc(C)c(C)c2)c(=O)n1CC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
JAK3 P52333 1/20 0.38
KDM4E B2RXH2 8/20 0.38
ALDH1A1 P00352 2/20 0.38
PLA2G7 Q13093 1/20 0.36
F2 P00734 1/20 0.34
RPS6KB1 P23443 2/20 0.34
POLB P06746 1/20 0.34
P2RX3 P56373 1/20 0.33
TP53 P04637 1/20 0.33
ASPH Q12797 1/20 0.33
RIOX2 Q8IUF8 1/20 0.33
KDM8 Q8N371 1/20 0.33
CCNT1 O60563 1/20 0.33
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ROCK2 O75116 1/20 0.32
CHEK2 O96017 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765785 0.88 KDM4E (0.40) JAK2JAK1JAK3KDM4EALDH1A1
SCHEMBL30765705 0.83 ALDH1A1 (0.38) JAK2JAK1JAK3KDM4EALDH1A1
SCHEMBL23460591 0.79 KDM4E (0.43) KDM4EALDH1A1F2POLBASPH
SCHEMBL30765933 0.78 KDM4C (0.45) JAK2JAK1JAK3KDM4EALDH1A1
SCHEMBL30765644 0.77 KDM4E (0.42) KDM4EALDH1A1F2POLBASPH
SCHEMBL23474380 0.77 KDM4E (0.41) JAK2JAK1JAK3KDM4EALDH1A1
SCHEMBL30765612 0.75 KDM4E (0.44) JAK2JAK1JAK3KDM4EALDH1A1
SCHEMBL23461141 0.73 KDM4E (0.46) JAK2JAK1JAK3KDM4EALDH1A1
SCHEMBL30765741 0.72 LMNA (0.41) KDM4EALDH1A1POLBLMNAHTT
SCHEMBL23461175 0.69 ALDH1A1 (0.42) JAK2JAK1JAK3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed